Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target dropped by Morgan Stanley from $788.00 to $730.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 9.83% from the stock’s previous close.

Several other research analysts also recently commented on the stock. Cantor Fitzgerald reduced their price target on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research note on Monday. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Finally, Guggenheim increased their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $787.71.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ REGN traded down $11.57 during midday trading on Wednesday, hitting $664.66. The company’s stock had a trading volume of 257,618 shares, compared to its average volume of 867,924. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a market cap of $70.27 billion, a P/E ratio of 16.18, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The business’s 50 day moving average is $648.64 and its two-hundred day moving average is $724.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the previous year, the business earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 37.46 EPS for the current year.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC grew its stake in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $226,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $3,183,000. Gabelli Funds LLC grew its position in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after buying an additional 55 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after buying an additional 5,120 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron to buy from hold, which can boost investor confidence in the stock’s near-term outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist reiterated a buy rating while setting a $769 price target, implying analysts still see meaningful upside. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC kept a buy rating even after lowering its price target, suggesting continued confidence in Regeneron’s fundamentals. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock with a favorable earnings surprise history, which may support optimism heading into the next report. Here’s Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada cut its target to $696 and kept a sector perform rating, a cautious update that still points to modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Broader biotech optimism, including comments that the sector could become “the hottest group in the market,” may be helping sentiment, though it is not Regeneron-specific. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 plan, a small insider sale that may still dampen sentiment. SEC filing for director sale

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.